US court upholds Merck & Co's Singulair patent
This article was originally published in Scrip
Executive Summary
A US federal judge has upheld the validity of Merck & Co's compound patent on its top-selling asthma drug, Singulair (montelukast sodium), in a ruling that prevents Teva Pharmaceutical Industries from marketing a generic until August 2012.